Novo Nordisk's diabetes medication, Ozempic (semaglutide) and weight-loss treatment Saxenda (liraglutide) are being investigated, following reports they may be associated with suicidal ideation The European Medicines Agency (EMA) is looking into adverse events flagged by the Icelandic Medicines Agency, relating to three cases of patients reporting suicidal ideation, Reuters reports. The investigation is set